Lutetium Lu 177 Vipivotide Tetraxetan trials for Prostate cancer

All Lutetium Lu 177 Vipivotide Tetraxetan trials · All Prostate cancer trials

Phase breakdown

Recruiting trials studying Lutetium Lu 177 Vipivotide Tetraxetan for Prostate cancer

• 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
  NCT07219147 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
  NCT06095089 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
  NCT05818683 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 15 locations
• Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
  NCT06526299 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
  NCT07698535 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)
  NCT06216249 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
  NCT06288113 · Phase: Phase 2 · Ages: No age limits stated · Sex: Male · 1 location
• Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
  NCT06632977 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 108 locations
• Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
  NCT07200830 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Male · 129 locations
• Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
  NCT06145633 · Phase: Phase 2 · Ages: No age limits stated · Sex: Male · 1 location

Common questions

How many trials study Lutetium Lu 177 Vipivotide Tetraxetan for Prostate cancer?

10 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.